Literature DB >> 3438310

Whipple's procedure plus intraoperative pancreatic duct occlusion for severe chronic pancreatitis: clinical, exocrine, and endocrine consequences during a 3-year follow-up.

M U Schneider1, R Meister, S Domschke, H Zirngibl, H Strebl, G Heptner, C Gebhardt, F P Gall, W Domschke.   

Abstract

The present investigation provides follow-up data (up to 36 months) of exocrine and endocrine pancreatic function, inflammatory activity, pain, and body weight in 23 chronic pancreatitis patients submitted to Whipple's procedure plus intraoperative Ethibloc occlusion of the remaining pancreatic duct system between January 1983 and February 1984. Clinically, Whipple's procedure plus intraoperative pancreatic duct occlusion resulted in almost complete and continuous cessation of pain as well as significant (p less than 0.05) increase in body weight. With regard to exocrine pancreatic function (Secretin-Pancreozymin test, plasma amino acid consumption test, Pankreolauryl test, fecal chymotrypsin determination), intraoperative pancreatic duct occlusion was shown to induce high-grade insufficiency and thus exocrine parenchymal atrophy in all patients. Simultaneously, the inflammatory process (represented by serum levels of trypsin, lipase, and pancreatic isoamylase) was terminated in all 23 patients. Endocrine pancreatic function, evaluated by serum levels of insulin and C-peptide measured under fasting conditions and subsequent maximal combined beta-cell stimulation as well as corresponding integrated hormone releases, was reduced by partial pancreas resection by about 50%, while there was no further impairment during the 36-month follow-up period in consequence of additional intraoperative pancreatic duct occlusion. Altogether, Whipple's procedure plus intraoperative Ethibloc occlusion of the residual pancreatic duct system seems suitable for termination of the inflammatory process and thus preservation of residual endocrine pancreatic function in chronic pancreatitis.

Entities:  

Mesh:

Year:  1987        PMID: 3438310     DOI: 10.1097/00006676-198711000-00016

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  [Pancreatic duct occlusion from the clinical viewpoint: exocrine and endocrine consequences].

Authors:  M U Schneider
Journal:  Langenbecks Arch Chir       Date:  1989

2.  Decreased serum essential and aromatic amino acids in patients with chronic pancreatitis.

Authors:  Krystian Adrych; Marian Smoczynski; Magdalena Stojek; Tomasz Sledzinski; Ewa Slominska; Elzbieta Goyke; Ryszard-Tomasz Smolenski; Julian Swierczynski
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

3.  Long-term assessments after pancreaticoduodenectomy with pancreatic duct invagination anastomosis.

Authors:  Yasuhiro Fujino; Yasuyuki Suzuki; Ippei Matsumoto; Tetsuya Sakai; Tetsuo Ajiki; Takashi Ueda; Yoshikazu Kuroda
Journal:  Surg Today       Date:  2007-09-26       Impact factor: 2.549

Review 4.  Surgical options in chronic pancreatitis.

Authors:  R A Prinz
Journal:  Int J Pancreatol       Date:  1993-10

5.  Severe chronic cephalic pancreatitis: use of partial duodenopancreatectomy with occlusion of the pancreatic duct in 289 patients.

Authors:  F P Gall; C Gebhardt; R Meister; H Zirngibl; M U Schneider
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

6.  Local resection of the head of the pancreas combined with longitudinal pancreaticojejunostomy in the management of patients with chronic pancreatitis.

Authors:  C F Frey; K Amikura
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

7.  Endoluminal radiofrequency ablation of the main pancreatic duct is a secure and effective method to produce pancreatic atrophy and to achieve stump closure.

Authors:  Anna Andaluz; Elzbieta Ewertowska; Xavier Moll; Adrià Aguilar; Félix García; Dolors Fondevila; Rita Quesada; Enrique Berjano; Luís Grande; Fernando Burdío
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.